<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02340299</url>
  </required_header>
  <id_info>
    <org_study_id>EA2/011/12</org_study_id>
    <nct_id>NCT02340299</nct_id>
  </id_info>
  <brief_title>Nasal HFOV Versus Nasal CPAP to Reduce Post-extubation pCO2</brief_title>
  <official_title>Nasal High Frequency Oscillation Ventilation Versus Nasal Continuous Positive Airway Pressure to Reduce Post-extubation pCO2 in Very Low Birth Weight Infants: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether nasal high frequency oscillation ventilation (nHFOV) immediately after&#xD;
      extubation reduces the arterial partial pressure of carbon dioxide (paCO2) at 72 hours after&#xD;
      extubation in comparison with nasal continuous positive airway pressure (nCPAP) in very low&#xD;
      birth weight infants (VLBWs).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized controlled clinical trial comparing nHFOV vs nCPAP immediately after extubation of&#xD;
      VLBW infants.&#xD;
&#xD;
      Intervention and treatment protocol as described for the two study arms.&#xD;
&#xD;
      Definition of treatment failure (infant meets at least one criterion):&#xD;
&#xD;
        -  Sustained pCO2 &gt;80 mmHg and pH &lt;7.20 confirmed by arterial or capillary blood gas&#xD;
           analysis in spite of optimized non-invasive respiratory support with maximum settings as&#xD;
           defined above.&#xD;
&#xD;
        -  Fraction of inspired oxygen (FiO2) &gt;0.6 to maintain peripheral oxygen saturation as&#xD;
           measured by pulse oximetry (SpO2) at 90-94% in spite of optimized non-invasive&#xD;
           respiratory support with maximum settings as defined above.&#xD;
&#xD;
        -  Reintubation (study patients may be intubated at any time, due to clinical&#xD;
           considerations, with or without reaching another criterion of &quot;treatment failure&quot;).&#xD;
&#xD;
      Sample size:&#xD;
&#xD;
      Assuming a variability of the paCO2 as previously reported for difficult-to-wean preterm&#xD;
      infants in our unit (Czernik C, J Matern Fetal Neonatal Med 2012) and a treatment failure&#xD;
      rate of 22% within 72 hours after extubation, we calculated a sample size of 34 patients in&#xD;
      each study arm to detect a difference in the paCO2 of 7 mmHg, using a two-sided significance&#xD;
      of 0.05 and a power of 0.8.&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      Sequence generation by an independent statistician and a study nurse. Block randomization&#xD;
      using at least two different block sizes. Allocation concealment using sequentially numbered&#xD;
      opaque sealed envelopes.&#xD;
&#xD;
      Data monitoring:&#xD;
&#xD;
      By an independent statistician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>paCO2 at 72 h After Extubation</measure>
    <time_frame>64 h to 80 h</time_frame>
    <description>Partial pressure of arterial carbon dioxide assessed between 64 and 80 hours, and on average 72 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pH at 2 h After Extubation</measure>
    <time_frame>within the first 6 h after extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>paO2 at 2 h After Extubation</measure>
    <time_frame>within the first 6 h after extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>paCO2 at 2 h After Extubation</measure>
    <time_frame>within the first 6 h after extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Base Excess at 2 h After Extubation</measure>
    <time_frame>within the first 6 h after extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH at 72 h After Extubation</measure>
    <time_frame>64-80 h after extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>paO2 at 72 h After Extubation</measure>
    <time_frame>64-80 h after extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Base Excess at 72 h After Extubation</measure>
    <time_frame>64-80 h after extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful Extubation</measure>
    <time_frame>72 h after extubation</time_frame>
    <description>Defined as the number of patients breathing spontaneously in their assigned treatment group for ≥72h without reaching the criterion of &quot;treatment failure&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Failure</measure>
    <time_frame>within 7 days after extubation</time_frame>
    <description>Defined as the number of patients reaching the criterion of &quot;treatment failure&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reintubation</measure>
    <time_frame>within 7 days after extubation</time_frame>
    <description>Defined as the number of patients being reintubated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highly Viscous Secretions</measure>
    <time_frame>within 72 hours after extubation</time_frame>
    <description>Defined as the documented number of episodes of airway obstruction due to highly viscous secretions per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Adverse Effects</measure>
    <time_frame>until discharge</time_frame>
    <description>Incidences of the following adverse effects: Intraventricular hemorrhage III°-IV° (Papile), surgical necrotizing enterocolitis, pneumothorax, pulmonary interstitial emphysema, persistent ductus arteriosus requiring surgical closure, retinopathy of prematurity requiring laser treatment and/or injection of bevacizumab, death or moderate to severe bronchopulmonary dysplasia (Jobe) at 36 weeks' gestational age, periventricular leukomalacia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Respiratory Support</measure>
    <time_frame>until discharge</time_frame>
    <description>Total duration of mechanical ventilation, total duration of supplemental oxygen, number of infants discharged with home oxygen</description>
  </secondary_outcome>
  <other_outcome>
    <measure>pH at 2 h After Switch to &quot;Rescue Treatment&quot;</measure>
    <time_frame>within the first 6 h after switch to &quot;rescue treatment&quot;</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>paO2 at 2 h After Switch to &quot;Rescue Treatment&quot;</measure>
    <time_frame>within the first 6 h after switch to &quot;rescue treatment&quot;</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>paCO2 at 2 h After Switch to &quot;Rescue Treatment&quot;</measure>
    <time_frame>within the first 6 h after switch to &quot;rescue treatment&quot;</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Base Excess at 2 h After Switch to &quot;Rescue Treatment&quot;</measure>
    <time_frame>within the first 6 h after switch to &quot;rescue treatment&quot;</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Successful Rescue</measure>
    <time_frame>72 h after switch to &quot;rescue&quot; treatment</time_frame>
    <description>Defined as spontaneous breathing for ≥72h after starting &quot;rescue&quot; therapy, without reaching the criterion of &quot;treatment failure&quot;</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <condition>Respiratory Tract Diseases</condition>
  <arm_group>
    <arm_group_label>nHFOV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.&#xD;
The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.&#xD;
For infants in the nHFOV-group who &quot;fail&quot; nHFOV (see definition below), but do not need immediate reintubation, a non-invasive &quot;Rescue-Treatment&quot; may be provided. The decision to attempt &quot;Rescue-Treatment&quot;, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nCPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.&#xD;
The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.&#xD;
For infants in the nCPAP-group who &quot;fail&quot; nCPAP (see definition below), but do not need immediate reintubation, &quot;Rescue-nHFOV&quot; via binasal prongs may be provided. The decision to attempt &quot;Rescue-nHFOV&quot; and the ventilator settings used are at the discretion of the attending clinician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nHFOV</intervention_name>
    <description>Extubation to ventilator-derived nHFOV using binasal prongs</description>
    <arm_group_label>nHFOV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nCPAP</intervention_name>
    <description>Extubation to ventilator-derived nCPAP using binasal prongs</description>
    <arm_group_label>nCPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age &lt;32+0 weeks&#xD;
&#xD;
          -  Birth weight &lt;1500 g&#xD;
&#xD;
          -  Received mechanical ventilation via an endotracheal tube for ≥120 h&#xD;
&#xD;
          -  Caffeine treatment according to unit guidelines&#xD;
&#xD;
          -  paCO2 &lt;65 mmHg with pH &gt;7.2&#xD;
&#xD;
          -  FiO2 25-40% to maintain SpO2 at 90-94%.&#xD;
&#xD;
          -  Time-cycled, pressure-controlled ventilation: PIP ≤22 cm H2O, PEEP ≤6 cm H2O; Volume&#xD;
             guarantee ventilation: Working Ppeak ≤22 cm H2O, PEEP ≤6 cm H2O; High frequency&#xD;
             oscillation ventilation: Pmean ≤12 cm H2O, Amplitude ≤30 cm H2O&#xD;
&#xD;
          -  Decision of the attending clinician to extubate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major congenital malformation requiring surgery&#xD;
&#xD;
          -  Duct-dependent congenital heart disease&#xD;
&#xD;
          -  Neuromuscular disease&#xD;
&#xD;
          -  Participation in another randomized controlled trial&#xD;
&#xD;
          -  Death before reaching the eligibility criteria&#xD;
&#xD;
          -  Hydrocortisone treatment at the time of enrolment&#xD;
&#xD;
          -  Chronological age &gt;28 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Czernik, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dpt. of Neonatology, Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 10, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2015</study_first_posted>
  <results_first_submitted>May 6, 2019</results_first_submitted>
  <results_first_submitted_qc>July 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2020</results_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Christoph Czernik</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>High Frequency Oscillation Ventilation</keyword>
  <keyword>Nasal Continuous Positive Airway Pressure</keyword>
  <keyword>Airway Extubation</keyword>
  <keyword>Prematurity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 13, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02340299/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>nHFOV</title>
          <description>Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.&#xD;
The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.&#xD;
For infants in the nHFOV-group who &quot;fail&quot; nHFOV (see definition below), but do not need immediate reintubation, a non-invasive &quot;Rescue-Treatment&quot; may be provided. The decision to attempt &quot;Rescue-Treatment&quot;, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.&#xD;
nHFOV: Extubation to ventilator-derived nHFOV using binasal prongs</description>
        </group>
        <group group_id="P2">
          <title>nCPAP</title>
          <description>Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.&#xD;
The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.&#xD;
For infants in the nCPAP-group who &quot;fail&quot; nCPAP (see definition below), but do not need immediate reintubation, &quot;Rescue-nHFOV&quot; via binasal prongs may be provided. The decision to attempt &quot;Rescue-nHFOV&quot; and the ventilator settings used are at the discretion of the attending clinician.&#xD;
nCPAP: Extubation to ventilator-derived nCPAP using binasal prongs</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>nHFOV</title>
          <description>Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.&#xD;
The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.&#xD;
For infants in the nHFOV-group who &quot;fail&quot; nHFOV (see definition below), but do not need immediate reintubation, a non-invasive &quot;Rescue-Treatment&quot; may be provided. The decision to attempt &quot;Rescue-Treatment&quot;, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.&#xD;
nHFOV: Extubation to ventilator-derived nHFOV using binasal prongs</description>
        </group>
        <group group_id="B2">
          <title>nCPAP</title>
          <description>Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.&#xD;
The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.&#xD;
For infants in the nCPAP-group who &quot;fail&quot; nCPAP (see definition below), but do not need immediate reintubation, &quot;Rescue-nHFOV&quot; via binasal prongs may be provided. The decision to attempt &quot;Rescue-nHFOV&quot; and the ventilator settings used are at the discretion of the attending clinician.&#xD;
nCPAP: Extubation to ventilator-derived nCPAP using binasal prongs</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19" lower_limit="15" upper_limit="28"/>
                    <measurement group_id="B2" value="16" lower_limit="13" upper_limit="19"/>
                    <measurement group_id="B3" value="17.5" lower_limit="13" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>paCO2 at 72 h After Extubation</title>
        <description>Partial pressure of arterial carbon dioxide assessed between 64 and 80 hours, and on average 72 hours.</description>
        <time_frame>64 h to 80 h</time_frame>
        <population>In patients that were reintubated within 72 h, the primary outcome, paCO2 72 h after extubation, could not be assessed. In the nCPAP group, all patients had to be reintubated within 72 h. The primary outcome, paCO2 72 h after extubation, could therefore only be assessed in the nHFOV group.</population>
        <group_list>
          <group group_id="O1">
            <title>nHFOV</title>
            <description>Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.&#xD;
The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.&#xD;
For infants in the nHFOV-group who &quot;fail&quot; nHFOV (see definition below), but do not need immediate reintubation, a non-invasive &quot;Rescue-Treatment&quot; may be provided. The decision to attempt &quot;Rescue-Treatment&quot;, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.&#xD;
nHFOV: Extubation to ventilator-derived nHFOV using binasal prongs</description>
          </group>
          <group group_id="O2">
            <title>nCPAP</title>
            <description>Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.&#xD;
The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.&#xD;
For infants in the nCPAP-group who &quot;fail&quot; nCPAP (see definition below), but do not need immediate reintubation, &quot;Rescue-nHFOV&quot; via binasal prongs may be provided. The decision to attempt &quot;Rescue-nHFOV&quot; and the ventilator settings used are at the discretion of the attending clinician.&#xD;
nCPAP: Extubation to ventilator-derived nCPAP using binasal prongs</description>
          </group>
        </group_list>
        <measure>
          <title>paCO2 at 72 h After Extubation</title>
          <description>Partial pressure of arterial carbon dioxide assessed between 64 and 80 hours, and on average 72 hours.</description>
          <population>In patients that were reintubated within 72 h, the primary outcome, paCO2 72 h after extubation, could not be assessed. In the nCPAP group, all patients had to be reintubated within 72 h. The primary outcome, paCO2 72 h after extubation, could therefore only be assessed in the nHFOV group.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" lower_limit="52" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>pH at 2 h After Extubation</title>
        <time_frame>within the first 6 h after extubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>paO2 at 2 h After Extubation</title>
        <time_frame>within the first 6 h after extubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>paCO2 at 2 h After Extubation</title>
        <time_frame>within the first 6 h after extubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Base Excess at 2 h After Extubation</title>
        <time_frame>within the first 6 h after extubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>pH at 72 h After Extubation</title>
        <time_frame>64-80 h after extubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>paO2 at 72 h After Extubation</title>
        <time_frame>64-80 h after extubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Base Excess at 72 h After Extubation</title>
        <time_frame>64-80 h after extubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Successful Extubation</title>
        <description>Defined as the number of patients breathing spontaneously in their assigned treatment group for ≥72h without reaching the criterion of &quot;treatment failure&quot;</description>
        <time_frame>72 h after extubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Failure</title>
        <description>Defined as the number of patients reaching the criterion of &quot;treatment failure&quot;</description>
        <time_frame>within 7 days after extubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reintubation</title>
        <description>Defined as the number of patients being reintubated</description>
        <time_frame>within 7 days after extubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highly Viscous Secretions</title>
        <description>Defined as the documented number of episodes of airway obstruction due to highly viscous secretions per patient</description>
        <time_frame>within 72 hours after extubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Adverse Effects</title>
        <description>Incidences of the following adverse effects: Intraventricular hemorrhage III°-IV° (Papile), surgical necrotizing enterocolitis, pneumothorax, pulmonary interstitial emphysema, persistent ductus arteriosus requiring surgical closure, retinopathy of prematurity requiring laser treatment and/or injection of bevacizumab, death or moderate to severe bronchopulmonary dysplasia (Jobe) at 36 weeks' gestational age, periventricular leukomalacia</description>
        <time_frame>until discharge</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Respiratory Support</title>
        <description>Total duration of mechanical ventilation, total duration of supplemental oxygen, number of infants discharged with home oxygen</description>
        <time_frame>until discharge</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>pH at 2 h After Switch to &quot;Rescue Treatment&quot;</title>
        <time_frame>within the first 6 h after switch to &quot;rescue treatment&quot;</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>paO2 at 2 h After Switch to &quot;Rescue Treatment&quot;</title>
        <time_frame>within the first 6 h after switch to &quot;rescue treatment&quot;</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>paCO2 at 2 h After Switch to &quot;Rescue Treatment&quot;</title>
        <time_frame>within the first 6 h after switch to &quot;rescue treatment&quot;</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Base Excess at 2 h After Switch to &quot;Rescue Treatment&quot;</title>
        <time_frame>within the first 6 h after switch to &quot;rescue treatment&quot;</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Successful Rescue</title>
        <description>Defined as spontaneous breathing for ≥72h after starting &quot;rescue&quot; therapy, without reaching the criterion of &quot;treatment failure&quot;</description>
        <time_frame>72 h after switch to &quot;rescue&quot; treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected until discharge from the neonatal unit. Patients were discharged approximately at 3 months of age.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>nHFOV</title>
          <description>Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.&#xD;
The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.&#xD;
For infants in the nHFOV-group who &quot;fail&quot; nHFOV (see definition below), but do not need immediate reintubation, a non-invasive &quot;Rescue-Treatment&quot; may be provided. The decision to attempt &quot;Rescue-Treatment&quot;, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.&#xD;
nHFOV: Extubation to ventilator-derived nHFOV using binasal prongs</description>
        </group>
        <group group_id="E2">
          <title>nCPAP</title>
          <description>Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.&#xD;
The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.&#xD;
For infants in the nCPAP-group who &quot;fail&quot; nCPAP (see definition below), but do not need immediate reintubation, &quot;Rescue-nHFOV&quot; via binasal prongs may be provided. The decision to attempt &quot;Rescue-nHFOV&quot; and the ventilator settings used are at the discretion of the attending clinician.&#xD;
nCPAP: Extubation to ventilator-derived nCPAP using binasal prongs</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Highly viscous secretions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>PD Dr. Christoph Czernik, principal investigator</name_or_title>
      <organization>Charité - Universitätsmedizin Berlin</organization>
      <phone>+49 30 450 ext 566122</phone>
      <email>christoph.czernik@charite.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

